You are here

  • Home
  • Archive
  • Volume 10, Issue 5
  • Correction: Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept

https://doi.org/10.1136/jitc-2022-004699corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Nguyen LS, Bretagne M, Arrondeau J, et al. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. J ImmunoTher Cancer 2022;10:e004699. doi: 10.1136/jitc-2022-004699.

    This article has been corrected since it was first published online. In the ‘Case-report’ section, the dosage for intravenous abatacept in combination with oral ruxolitinib has been corrected to ‘15 mg two times daily’.